
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The APA has approved proposed revisions to the new edition of the Diagnostic and Statistical Manual of Mental Disorders to be published in May 2013.






